MedTrace Logo

1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers

NCT02168543 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2014-06-20

No results posted yet for this study

Summary

* Locally delivered Alendronate (ALN) have potent inhibitory effect on bone and increases new bone formation in chronic periodontitis patients
* Till date no study has reported the effect of local delivery of ALN in chronic periodontitis patients among smokers. Hence the aim of this study is to investigate the clinical and radiographic effects of locally delivered ALN as an adjunct to the non surgical treatment in smoker chronic periodontitis patients.

Conditions

  • Chronic Periodontitis

Interventions

DRUG

Alendronate

DRUG

Placebo

Sponsors & Collaborators

  • Government Dental College and Research Institute, Bangalore

    lead OTHER

Principal Investigators

  • Dr. Anuj Sharma, BDS, MDS · RIMS, Ranchi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-01-31
Completion
2011-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02168543 on ClinicalTrials.gov